It has now been found that after administration to a diseased person or
person that is at risk for developing such disease of a neutraceutical or
pharmaceutical composition that comprises: a) a lipid fraction
comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic
acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction
comprising proteinaceous material from non-human origin which provide at
least cysteine and/or taurine; and c) a mineral fraction comprising at
least one of manganese and molybdene,the health of these persons
improves. Membrane function of several types of mammalian cells improves,
which allows efficient treatment of immune related disorders, such as
allergy, autoimmune diseases, cancer, cognitive dysfunction and other
diseases of the nervous system, neuropathies, such as diabetic
neuropathies and neuropathic pains, neuronal damage during insulin
resistance, and gut diseases and support of the development of gut and
lung function during growth or recovery.